Floatz logo

Fexagratinib

Carcinoma, Squamous Cell

University of BirminghamSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

29 Active assets in the Carcinoma, Squamous Cell cohort.

Asset / SponsorPhaseRating
Carboplatin
Neonc Technologies, Inc.
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
University of Oxford
Phase 3BB
Docetaxel
Hummingbird Bioscience
Phase 2BB
Eloxatin
University of Oxford
Phase 3BB
Fibrin Sealant
Oxford University Hospitals NHS Trust
Phase 4BB

View all 50 →

Same molecule, other indications

Fexagratinib is also rated in:

squamous cell lung carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
59 / 100
View asset →
adenocarcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →